I imagine this... probably ... and it’s just the beginning.According to the indicator at the base of the advisor Marketmiracle the CLVS stock is accumulating capitals and is ready for an explosion.
Clovis Oncology is one of the best-selling low-cost titles but produces a drug capable of improving the lives of cancer patients worldwide.
Clearly the money devoted to biotech and pharmaceutical companies during the covid period was directed to vaccine manufacturers but now, that the clouds are clearing up and the covid danger seems to have drifted away, it seems to be heading back to what are the possible cures for the diseases of the century, namely cancer, This is also demonstrated by the recent rise in prices of $AHT, which is a cancer care company ( see related idea)
I imagine a movement of the title as the one indicated in the graph, but I have the feeling that it will only be the beginning, the company a few years ago priced much but much more and its trails are successful as demonstrated by the recent results.
Investing in a society like this is also a way to help medicine and the entire human race..
I did a search on the fundamental analysis sites that I use as a reference and it seems according to their analysts that the current price of Clovis Oncology is absolutely below the right value, which is given around 50 USD
i.imgur.com
I certainly put a chip on Clovis ... I think it’s a great opportunity.
Scrolling at the bottom of this page you will find the advisor Market Miracle who gave a few days ago the input signal on $CLVS.
Cancer
DR JI IS BACK FOR HIS REVENGE. SRNE FALLING WEDGE AND GAP FILL DR JI IS BACK FOR HIS REVENGE. SRNE FALLING WEDGE AND GAP FILL TO 12s can be seen.
Dr Ji will always burn the shorts. Shorts, get ready to cover yourself.
CLVS - Cure for the market cancer!This company is going to be huge.
Fundamentally :
It's already passing the Phase 3 ARIEL4 study.
Revenue has been beaten in last quarter report. (although there was a small overestimate for the profit(loss) per share)
The MACD indicator is bouncing back (also the price is pushing through the Moving Averages).
Price is now in the channel (2 thick red dot lines).
It's rebouncing from the resistance(green line coming from the bottom).
RSI + MF looking good!
Divergance indicator is saying it's going to rise!
Remember : not financial advise, just see what's going to happen.
Use fundamentals to find a stock, use technicals to find moment to buy it.
Good luck!
ODT Odonate Therapeutics all time low! Buy oportunity?Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company.
As of December 31, 2020, Odonate had $157.3 million in cash, compared to $180.5 million as of December 31, 2019. (businesswire.com)
ODT Odonate Therapeutics MARKET CAP 147.784M
That`s less than its cash balance!
The indicators showed a sell signal just before the selloff.
I know it`s a speculative buy, buy it worth the risk?
What is your opinion?
If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
HALBERD CORPORATION· Current Price – $0.0419
· Best Case Scenario PT over 1$
· Market Cap – $11 million
· Debt – 0
Halbert Corporation
Are a biomedical company with a clear aim to revolutionize the world of medicine. They are working towards a creation of variety of antibodies and treatments using extracorporeal techniques (outside of body). They believe they have the technology to cure diseases like, Covid-19, PTSD, Cancer, CTE, tuberculosis, malaria, strokes and heart attacks, blood sepsis, Alzheimer’s Disease.
In the last 8 months they have secured 7 provisional patents (which give the global rights) to technology of treating severe Covid-19 patients, Covid-19 nasal spray, antibody cocktail to boost immune system against Covid - 19 and recently developed two new antibodies that no other big pharma has, which allows them detect Covid-19 in matter of minutes using saliva or blood samples. Furthermore, are working with $GRPS to develop anti-addiction patches (alcohol, drugs, nicotine).
To achieve their further goals they have carefully selected to partner with Arizona State University (who have won the first place in innovation for the last 6 years going in the USA, higher than MIT or Stanford). This partnership has already delivered amazing milestones and they are already working towards filing for new joint provisional patents. Halbert has 0 debt, yes ZERO and been receiving funding in 2 million chunk donations due to promising results. Halberd’s corporate charter also prohibits them from issuing any kind of convertible financial instrument, debt or preferred stock, however the corporation shall be able to issue warrants or options.
Management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.
Furthermore, the ultimate catalyst, which seems quite likely is for Halbert to partner or licence their technology to one of the big pharma as the CEO, William has mentioned so on multiple occasions. In the past, he has been approached by the big pharma (Pfizer and Novartis), and hopes the same will happen with their revolutionary technology.
Issued Patents
2014 - Sequential Extracorporeal Treatment of Bodily Fluids
2015 - Utilization of Stents for the Treatment of Blood Borne Carcinomas
Provisional Patents
11/2020 - Fluorescent Antibody’s in Covid-19 Detection & Treatment
10/2020 - Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus).
10/2020 - Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus
09/2020 - Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans
04/2020 - Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus
04/2020 - Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients
03/2020 - Method for Treating and Curing Covid-19 Infection
Future Patents
During podcasts and interviews the CEO said he will announce another 2 patents soon. They are waiting to achieve provisional status to ensure the technology is safe. Further patents are in the pipeline as CEO’s devised a strategy to secure as many patents as they can, of which they could then either licence or partner on developing on joint ventures with big pharma.
Upcoming Catalyst 2021
· 2 patent provisional applications yet to be announced
· Development of antibody cocktail vitamins to boost immune system against Covid-19 (Q2 launch and start to generate revenue)
· Development of Covid-19 Nasal Spray
· Commercial development of Covid-19 test using saliva or blood (takes only a minute no nasal swap which is uncomfortable)
· Patent Licencing to other pharma companies – they produced antibodies that are stronger than some of the big pharma
· Partnerships and joint ventures with other organizations
· Discovery of new treatments and patent fillings
· Further development of extracorporeal technology to treat cancer, PTSD, Alzheimer’s, blood sepsis, CTE
· Anti-addiction patches
Sociability Factor
In penny stock market, especially during current times (rise of social media and social traders) the CEO’s or the organization being sociable, sharing achievements, milestones, ethos and so on can have a massive impact on the share value. In this regard, Halberd’s corporation in my view would score high points. They tend to release anywhere between 2/5 press releases a month in which various milestones would be announced via text, video interviews or podcasts.
Senior Leadership Team
The CEO’s aim was to ensure that they develop a very cohesive team of talented people to achieve greatness. Here below I have listed a few KEY members including bio snapshots.
Business Advisory Board
The CEO – based on the videos and podcasts that are available (6+) of William A. Hartman sounds very ambitious and driven on a mission to be the best in the industry and revolutionize medicine.
He believes Halberd corporation share value should be worth $1 per share. This may sound like very ambitious venture for some, however, let us not forget he founded and headed separate business group within TRW Automotive with plants in the U.S., Mexico and Europe that produced combined annual sales of $1.3 Billion – this shows extreme capability. He has also worked as COO for Nanologix, Inc, President and CEO of Premier Biomedical. I would recommend checking out any of his interviews to feel his passion.
Carl Eller - retired NFL Pro Football Hall of Famer, and President of the NFL Retired Players Association, was drafted in 1964 as the league’s 6th pick overall by the Minnesota Vikings, he became a major factor as a defensive end with the unit known as the “Purple People Eaters.” Eller became a six-time Pro Bowl player who appeared in four Superbowls and is currently focused on helping former players transition into retirement.
Alec Torelli - is an entrepreneur, author, motivational speaker and professional poker player who has worked with various companies to apply his life experiences/lessons from poker, in a practical manner, to carry out their corporate visions, increase sales and/or improve service delivery while creating meaningful lives for their employees.
Scientific Advisory Board
Mitchell S. Felder, MD - is a prolific inventor. He is a Board Certified Neurologist and former CEO, President, Chairman and founder of Infectech and Nanologix, and currently serves as Locum Tenens Attending Neurologist with UPMC Pennsylvania
Dr. Felder has authored or co-authored six publications, three studies and has currently 21 issued patents. Dr. Felder was the Acting Chief of the Department of Neurology, Sharon Regional Health System from 1989 until 2001. Dr. Felder served as the Acting Chief of the Department of Neurology at the William Beaumont Army Medical Center in 2011.
Dr. Qiang (Shawn) Chen, who is the Principal Investigator at ASU, in charge of the research and development for Halberd Corp:
Take a look at his research projects over the last 4-5 years and you see why this HALB/ASU cooperation is a marriage made in heaven. Only weeks ago, Halberd signed another R&D-agreement with GreenBioAZ inc, it's a start up from Arizona State University and will do research for Halberd's radiofrequency technology. Dr. Chen is CEO of GreenBioAZ
Patricio Reyes, MD, FAAN - a board certified neurologist and neuropathologist, and Chief of Neurology/TBI/Alzheimer’s Disease/Cognitive Disorders at the VA Medical Center in Phoenix, Arizona and is a Board Member of the Retired National Football League Players Association. Dr. Reyes is a board member, and former Chair of the Education Committee and 2009 Distinguished Educator of the Association of Ringside Physicians. HALB has access to the VA Hospital Group because of Dr. Reyes.
Timeline of Key Press Releases
I have gone through the list of all of their press releases (they post regularly) and compiled key updates here below:
April 6, 2020 - Halberd announces agreement to retire 192,000,000 outstanding common shares and reduced authorized shares of common stock to 1,000,000,000.
April 8, 2020 – Halberd, Premier Biomedical ($BIEI) and Gold River Productions ($GRPS) announce the signing of a multi-faceted agreement for ongoing R&D into a potential treatment and cure for Covid-19 as well as development of Premier’s Anti-Addiction Patch.
July 1, 2020 - Halberd establishes United Kingdom subsidiary to facilitate access to European research facilities and markets to establish a global footprint.
July 13, 2020 - Halberd’s corporate charter prohibits it from issuing any kind of convertible financial instrument, debt, or preferred stock.
August 4, 2020 - Halberd secures $2 Million for Covid-19 Research
August 31, 2020 - Halberd signed an agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments.
September 21, 2020 - Covid-19 Research Program Progress – Successful Covid Spike Protein Disease Antigen
September 24, 2020 - Successful creation of a fluorescent antibody, that will help them create a rapid Covid-19 test using saliva or a drop of blood. This approach will allow for accurate test results in a matter of minutes – believe travel industry may benefit from this approach.
October 8th, 2020 – CEO’s letter of updates and accomplishments
October 13, 2020 – Halberd and ASU Develop Antibody Against Covid-19, pursuing new joint patent.
October 19, 2020 – in process to filing a new joint patent with AUS for creation of a new class of anti-Spike protein monoclonal antibodies against Covid-19. This protein will allow extremely rapid identification of the Covid-19 virus in nasal mucus, saliva, and blood.
October 29, 2020 – Strategic plan curing blood sepsis, Alzheimer’s Disease, Heart Attack and Stroke using extracorporeal process
November 12, 2020 – Patent pending for Covid-19 detection test from saliva or blood in minutes.
December 1, 2020 – Halberd re-organizes advisory board.
December 17, 2020 - Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19
December 23, 2020 - Halberd Produces a Second Monoclonal Antibody Against Covid-19 Spike Protein – “Mathematically speaking, if each is 90% effective independently, then, absent any interrelationship of the two applications, the combination should be 99% effective. In other words, the prospect of obtaining diagnostic test false positives or false negatives is substantially reduced when antibodies work in tandem”
January 4, 2021 - Halberd Corporation 2020 Year End CEO Letter, looking forward to 2021
January 14, 2021 - Halberd Develops Medication to Boost Immune System Against Covid-19
February 16, 2021 - Halberd has engaged GreenBioAZ to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease.
March 2, 2021 - Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater - “We are excited about the progress being made in developing Halberd’s effective proprietary antibodies against Covid-19. These results put our antibody in the same realm of effectiveness as the best-known competitive SARS-COV-2 antibodies.
Since posting links may take an excessive amount of space here, you can find all the press releases here and search by date, plenty more to see that are not included in my post -
Hope people found this helpful and I look forward to seeing what the future holds for $HALB!
Tight Risk Reward, Good CompanyMersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need.
After an insider at Mersana Therapeutics bought shares following a May 2020 selloff triggered by an interim data release, the stock rallied over 400% during the next eight months.
Another bounce back may emerge again with an insider purchasing shares after a one-day plunge of nearly 30% on tepid but still encouraging data from its lead ADC asset.
A 180-patient single-arm registrational trial is set to be initiated for XMT-1536 in the treatment of platinum-resistant ovarian cancer this quarter.
With early-stage clinical data due from both its candidates in the treatment of NSCLC adenocarcinoma in 2H21, Mersana merited another look.
I like it long here as tight risk-reward play.
nice set-up going into next week+ back-tested the previous AH. looking to re-test current AH and climb to a new AH.
+ The more Saphyrs deployed = More Rev./Earnings = Higher Share Price.
+ 10,000 Deployed Saphyrs GOAL 2021 according to CEO Eric. $14 PT was given based on only 600 Deployed Saphyrs. $14 x 16.666 = $233.33 PT .
+ Cheers to a fun week ahead. It's been a long time coming.
I hate Cancer, I hate Shorts but...Shorts are doing the loyal investors a favor, they are man-making a solid resistance level to spring board from. When this hits $20, it will happen fast more than likely within hours... Just get in and sun block up... this is a long term play, not a spac, a P&D, or a penny stock... what you are witnessing is magic and it only happens once every decade or so... cheers.
Why SELLAS Life Sciences Is Surging Premarket?Why SELLAS Life Sciences Is Surging Premarket?
SELLAS Life Sciences is captivating investors thanks to its late-stage cancer vaccine
Thanks to some news in December in the biopharma space, SLS stock is racing higher. So what was that news? And what else do you need to know?
its leading candidate Galinpepimut-S is making its way through Phase 3.
This immunotherapy targets the Wilms Tumor 1, which is the leading cancer antigen. Essentially, the company believes that this therapy, which is given via vaccine, reduces the immune response in a patient and has the ability to delay the relapse of cancer. Although SELLAS Life Sciences is testing it for a variety of cancers, it is currently in Phase 3 trials for acute myeloid leukemia.
This lead candidate is where the massive move in SLS stock comes from.
Importantly, SELLAS Life Sciences had some big news of its own in december. While its leading immunotherapy candidate remains in clinical trials, it entered a license agreement with China-based 3D Medicines. Through this deal, 3D Medicines will handle developing and commercializing Galinpepimut-S in mainland China, Hong Kong, Taiwan and Macau. According to a company press release, this could net $202 million in license fees for SELLAS. It also could bring an upfront payment of $7.5 million sometime this quarter.
it looks like another company is responsible for the move in SLS stock.
What do I mean? Well, in december we saw a major rally in Greenwich LifeSciences (NASDAQ:GLSI). Ahead of a conference, the company shared promising Phase 2b data on its breast cancer immunotherapy. Importantly, Greenwich LifeSciences is evaluating GP2 as a therapy for patients who have already undergone surgery for breast cancer. And according to the report yesterday, GP2 has reduced the recurrence rate of cancer in trial participants to 0%.
How does this tie into SELLAS Life Sciences? Well, GP2 and Galinpepimut-S are both unique immunotherapies that rely on vaccination as a delivery method. Essentially, both treatments are cancer vaccines. Both treatments are also quite innovative, representing potential advancements in the realm of cancer care. This means that with a more than 2,000% rally from GLSI stock, many investors may be rooting for the same with SLS.
Remember though, this is a tiny company that must continue to navigate clinical trials. Keep an eye on SLS stock, but proceed with caution.
IOVA - IOVANCE FINISHED FUELING UP AND ABOUT TO TURN ON ENGINEIovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in the pivotal study in patients with metastatic melanoma and cervical cancer. In addition, the company's TIL therapy is being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including head and neck and non-small cell lung cancer. A clinical study to investigate Iovance T cell therapy for blood cancers called peripheral blood lymphocyte (PBL) therapy is open to enrollment.
What an amazing opportunity. RISK 5% REWARD 22% 4.44 RISK TO REWARD RATIO
Enough cash on hand ~$720M cash (9/30/20) to last 3 years of R&D
2021 - Year to get some FDA News - HUGE POTENTIAL MARKET FOR CANCER TREATMENT
Research/ Study showing promise.
Developing Iovance manufacturing facility plans for commercialization 75 Million$ Investment scheduled for completion this year.
ATRA growth potentialAtara Biotherapeutics , Inc. (Nasdaq: ATRA ), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases
"Atara made significant progress in 2020 and is well-positioned for a strong 2021," said Pascal Touchon, President and Chief Executive Officer of Atara. "As the most advanced allogeneic T-cell therapy company, nearing initiation and subsequent completion of a rolling BLA for our lead product candidate tab-cel®, we are making key investments in commercial infrastructure to ensure delivery of this potentially transformative therapy to patients in dire need. Atara also anticipates significant progress throughout 2021 on ATA188 for progressive MS with multiple data read-outs and, after recent productive interactions with the FDA, is poised to expand enrollment in the RCT and conduct an interim analysis in H1 2022."
Let's make some SERIOUS money! (CGIX)Seeing a turn in cancer genetics incorporated... looks juicy.
Triple bottom structure with a recent falling wedge breakout on the overall expanding downward channel.
Each time on the turning point of this major multi year support we saw major impulsive moves shortly after.
Given that the price in time now is at a much lower discount compared to history. I think that is why we are seeing the triple bottom of accumulation. This correction to these lows also has been a bigger move just in general based off history.
This could be the beginning of a major bull cycle.
I feel good sitting in this one here.
Another plus is that this has a low float.
Anything I trade will always have a low float. (Less Outstanding Shares)
Remember I trade long term. I look for major multi year turning points in markets. The longer I can hold a trade, the better! I specifically analyze the weekly and the monthly, nothing else!
Thanks for checking out my analysis, check out some of my extra work on my page.
Synthetic Biologics Bullish MomentumSynthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol.
A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis. Patients receiving SYN-004 also demonstrated significantly better maintenance and recovery of the gut microbiome as well as lower incidences of new colonization by opportunistic and potentially pathogenic microorganisms such as VRE. (Source: prnewswire.com)
Please leave me a message if you want to test the buy and sell indicators that i am using.
Cancer Treatment - Ready to SpikeIt looks like this stock is ready to spike.
On 6/10/2020, NK said its NK cells appear to be resistant even to acute hypoxia and are capable of maintaining tumor killing activity in conditions comparable with a suppressive tumor microenvironment.
Long
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
OGEN Long into and past earnings! Starting Today!AMEX:OGEN is going to rip into earnings then pull back right before then pop for 100% or more post earnings. Here are my price targets placed for the next week every few days starting with next Monday.
DD:
OGEN has
*1 drug for Oral Mucosis just finished Phase 2 trial, FULL data will be release on earnings call and ironically at the same time they have $15 Million worth of Warrants that will expire the day before. :) Also OGEN as obtained FDA Fast Track approval for this drug and marketing agreements completed in Europe to put it on the shelves immediately if Phase 2 data is good.
*1 drug for lowering cholesterol by 70% currently in Phase 1trial, expect results and Ph2 announcement mid/early summer.
*$21 Million cash on hand with burn rate of less than 10 Million per year.
*This Monday OGEN bought a COVID19 trial drug company with 4,000,000 shares or roughly $1 Million.
Trading in a channel, well established bases in this range over the last year or two, no need for extra funding for at least 1 year.
Best Penny Stocks 🚀 to buy and watch in May 2020 NASDAQ:CLVS
😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks
FDA date of approval - 15.05.2020
Our Strategy with this Stock :
This company provides prostate cancer therapy . And as you can see there is huge previous spikeability in the company regarding their previous drug in their pipelines . It's going to be the first targeted therapy for prostate cancer Which alone brings a lot of news attention to the analysts already but the average price for the stock to $20 , which is my personal opinion I think it's very far from reality. I'm looking for a price of about 15 to $16 Max !!!
I put my alarm at 9.6$ . to monitor any anticipatory run up
What’s the real story :
The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply .
How can you actually use this ?
We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨🎓.
The Best Part
You can follow me and apply my trades for FREE !!!
QUESTIONS ?
Please comment below , what you have in mind 😊
Is $MBRX- The Best Biotech with the most upside Potential Is $MBRX- The Best Biotech with the most upside Potential
Just announced a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors. Company has a relatively small OS under 25 Mil and float under 15 Mil . The company is working with the most prestigious cancer centers to treat a broader range of the most difficult cancers like pancreatic cancer. There is a huge unmet medical need in treating these hard to treat cancers and $MBRX break through with STAT3 inhibitors is a game-changer for treating cancer patients.
As thing progress I expect this to have 5-10x potential in the relative short term and possible a 50x + in the long term..
One you might want to research and stick away in your IRA ..
As i write this stock is 2.05 , recent offer was done ar 2.10 so you know institutional savy investors see major upside and are getting involved at these levels..
Seattle genetics $SGEN#SeattleGenetics is doing several impressive studies which helped stock price moved up.They stayed strong during the crash. It is doing well so far but it may stall for a while because of the coming resistances.
Davita - now a BULL trend Technicals analysis WEEKLY
Davita broke a downtrend channel, and is now in a consolidation above the 200SMA. (Bull)
50SMA is now crossing above the 200SMA. (Bull)
OBV and RSI show divergence, as they have moved in oposite directions since early August. (Short). However... on a daily chart , we see a decent uptrend since early June.
Headlines / Fundamental
On July 10th:
President Donald Trump on Wednesday signed an executive order reimbursing for kidney transplants and reducing the reliance on the costly treatments at dialysis clinics.
Analyst fair value target price is $79. Meaning 38% undervalued .